{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:34:16Z","timestamp":1789533256051,"version":"build-2803163510"},"reference-count":56,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Cellular Molecular Medi"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bruton tyrosine kinase (BTK), the primary target of BTK inhibitors, is a key enzyme in the proliferation and survival pathway of neoplastic B\u2010cells. BTK inhibitors are approved in many hematologic malignancies: chronic lymphocytic leukaemia, mantle cell lymphoma, marginal zone lymphoma, Waldenstr\u00f6m macroglobulinaemia and follicular lymphoma. Second\u2010generation BTK inhibitors display high target selectivity thus resulting in a reduction in off\u2010target and off\u2010tissue effects, better therapeutic index and improved tolerability. This paper summarizes the mechanisms of action of first and second generation BTK inhibitors and elucidates results in any disease setting, with a precise focus on zanubrutinib.<\/jats:p>","DOI":"10.1111\/jcmm.70170","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T06:04:16Z","timestamp":1738303456000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5633-7313","authenticated-orcid":false,"given":"Alessandro","family":"Broccoli","sequence":"first","affiliation":[{"name":"IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d  Bologna Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche Universit\u00e0 di Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Del Re","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine University of Pisa  Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato\u2010Oncology University of Milano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d  Bologna Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche Universit\u00e0 di Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.262063"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.1046"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1039\/D0SC06122K"},{"key":"e_1_2_9_7_1","first-page":"483","article-title":"Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia","volume":"39","author":"Parmar S","year":"2014","journal-title":"PT"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15087"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1978288"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2856"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2005943"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-870238"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018884940"},{"key":"e_1_2_9_18_1","article-title":"Acalabrutinib versus investigator's choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia P","year":"2022","journal-title":"Hema"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01485-x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02238-7"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00884-4"},{"key":"e_1_2_9_24_1","article-title":"BGB\u20103111, a highly specific BTK inhibitor, is well tolerated and highly active in Chinese patients with relapsed\/refractory B\u2010cell malignancies: initial report of a phase 1 trial in China","volume":"130","author":"Zhu J","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0575-9"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6473"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004074"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014162"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00555"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.6426"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30210-8"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006449"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02830"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003121"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18368"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010668"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804641"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8853"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010298"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35114"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00843"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006083"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002183"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022369"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.09.002"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13651"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1159\/000528019"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00320-9"}],"container-title":["Journal of Cellular and Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jcmm.70170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T09:05:34Z","timestamp":1750151134000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcmm.70170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/jcmm.70170"],"URL":"https:\/\/doi.org\/10.1111\/jcmm.70170","archive":["Portico"],"relation":{},"ISSN":["1582-1838","1582-4934"],"issn-type":[{"value":"1582-1838","type":"print"},{"value":"1582-4934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"2024-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70170"}}